tbuckley/cabot-search huggingface dataset:
P3 Pilot study to test the feasibility of a psychological support workshop for patients newly diagnosed with Idiopathic Pulmonary Fibrosis (IPF) and their families: Abstract P3 Table 1
Authors: J Cove, AM Russell, J Wright, C Hogben, M Kokosi, V Mak, F Chua, A Wells, AM Doyle, E Renzoni
Journal: Thorax (2015)

<h3>Introduction</h3> IPF is associated with a poor prognosis, high symptom burden and limited treatment options. Psychological reactions are comparable to those seen in cancer patients, yet support services for IPF patients are less well developed. There is an urgent demand to develop Interstitial Lung Disease (ILD) services that better support the psychological needs of IPF populations. The aim of this pilot study is to characterise the psychological needs of both patients and carers and to test the feasibility of a workshop approach. <h3>Methods</h3> Consultant ILD physicians identified patients recently diagnosed with IPF at our Unit, and referred them to the clinical nurse specialist. Patients were invited to attend a half day workshop with an accompanying 'guest'. The workshop, led by a clinical psychologist, included didactic teaching, interactive discussions and experiential learning. Topics covered coping with low mood and anxiety, symptom control and transitions towards the end of life. Four members of the clinical team were present throughout as observers and to provide support. Demographic information; PHQ-9 and GAD-7 scores were collected (Table 1). Participants completed a semi-structured questionnaire at the end of the workshop. Framework analysis identified themes around the impact of attending the workshop. <h3>Results</h3> 13 patients and 16 family members attended the workshop. Participants reported benefiting from peer support; identifying with others. They felt emotionally supported through sharing experiences and appreciated the chance to learn about practical ways of managing symptoms and accessing other sources of support. All respondents said they would recommend the workshop to others diagnosed with IPF and their families. Participants reported that more medical information about IPF, its progression and prognosis would have been useful. Suggestions included requests for a larger venue and more information on oxygen. <h3>Conclusions</h3> Preliminary data suggests attendance at a workshop addressing psychological issues is feasible and is perceived to be a positive experience by patients diagnosed with IPF and their families. Future workshops will include more time for group discussion to facilitate peer support. A further two workshop are planned in July and September. Successive evaluations will continue to inform the development of subsequent workshops.
Clinical Activity of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Patients with CLL Previously Treated with an Inhibitor of B-Cell Receptor Pathway Signaling
Authors: Jeff P. Sharman, Andrei R. Shustov, Mitchell R. Smith, Thomas E. Boyd, Christopher Hagenstad, Kathryn S. Kolibaba, Steve Abella, Jing He, Clarence Eng, Jing Hu, Anita Reddy, Siddhartha Mitra, Christopher A. Yasenchak, Farrukh T. Awan
Journal: Blood (2015)
Role of the Microenvironment in Liver Metastasis: From Pre- to Prometastatic Niches
Authors: Pnina Brodt
Journal: Clinical Cancer Research (2016)

Abstract Liver metastases remain a major barrier to successful management of malignant disease, particularly for cancers of the gastrointestinal tract but also for other malignancies, such as breast carcinoma and melanoma. The ability of metastatic cells to survive and proliferate in the liver is determined by the outcome of complex, reciprocal interactions between tumor cells and different local resident subpopulations, including the sinusoidal endothelium, stellate, Kupffer, and inflammatory cells that are mediated through cell–cell and cell–extracellular matrix adhesion and the release of soluble factors. Cross-communication between different hepatic resident cells in response to local tissue damage and inflammation and the recruitment of bone marrow cells further enhance this intercellular communication network. Both resident and recruited cells can play opposing roles in the progression of metastasis, and the balance of these divergent effects determines whether the tumor cells will die, proliferate, and colonize the new site or enter a state of dormancy. Moreover, this delicate balance can be tilted in favor of metastasis, if factors produced by the primary tumor precondition the microenvironment to form niches of activated resident cells that promote tumor expansion. This review aims to summarize current knowledge on these diverse interactions and the impact they can have on the clinical management of hepatic metastases. Clin Cancer Res; 22(24); 5971–82. ©2016 AACR.
GW26-e4736 A Meta-Analysis of the Comparative Efficacy and Safety of Ablation for Paroxysmal Atrial Fibrillation With and Without the Use of Contact Force Sensing Catheter
Authors: Wenkui Lv, Xianhui Zhou, Yaodong Li, Jianghua Zhang, Qiang Xing, Qina Zhou, Wenhui Zhang, Yanmei Lu, Ling Zhang, Baopeng Tang
Journal: Journal of the American College of Cardiology (2015)
Chromosome 9 and 22 Breakpoints Cluster Regions Definition of Deleted Sequences on der(9) in Chronic Myeloid Leukemia.
Authors: Francesco Albano, Luisa Anelli, Antonella Zagaria, Alessandra Pannunzio, Domenico Pastore, Antonio Cuneo, Roberta La Starza, Lucia Sebastio, Nicoletta Testoni, Vincenzo Liso, Mariano Rocchi, Giorgina Specchia
Journal: Blood (2005)
Lidocaine Inhibits Proliferation and Promotes Cluster Formation of Bone Marrow Mesenchymal Stem Cells Cultured in High Glucose Plus Serum Deprivation DMEM.
Authors: Ting Zou, Bei Yang, Xia ying Lu, Ming Di Xiong, Xiu li Ni, Da Lei Zhang, Xin chang Wang, Jing lei Wang, Lei Wu, Si fan Xu, Xiao chun Yu, Jun hong Gao, Zhihong Wang
Journal: Blood (2009)
Systematic Review and Meta-analysis Show 3% of Patients With Celiac Disease in Spain to be Negative for HLA-DQ2.5 and HLA-DQ8
Authors: Fernando Fernández-Bañares, Beatriz Arau, Romina Dieli-Crimi, Mercè Rosinach, Concepción Nuñez, Maria Esteve
Journal: Clinical Gastroenterology and Hepatology (2016)
miR34s in Normal and Malignant B-Cells: miR34A Plays a Dominant Role in Normal B-Cells, and aggressive Diffuse Large B-Cell Lymphoma Carry Combined Lesions of TP53, MIR34A, and MIR34B/C
Authors: Christoffer Hother, Fazila Asmar, Gorjan Kulosman, Marianne B. Treppendahl, Ditte Reker, Ulrik Ralfkiaer, Anja Pedersen, Michael B. Møller, Peter De Nully Brown, Kirsten Grønbæk
Journal: Blood (2012)
GW26-e0753 Long-term efficacy and safety of Drug-eluting stent Versus Bare-metal Stent Implantation in Patients with Acute Coronary Syndrome: Clinical and Angiographic Follow-up
Authors: Tongku Liu, Feng Sun, Hongyan Ma, Shiyu Zheng, Runzuo Shao, Jinggui Zhang
Journal: Journal of the American College of Cardiology (2015)
INTEGRATING SPORT &amp; EXERCISE MEDICINE IN TO A ‘LATE EFFECTS CLINIC’ FOR CHILDHOOD CANCER SURVIVORS: DEVELOPING CARE PATHWAYS TO IMPROVE SERVICE PROVISION
Authors: G Evans, H Gleeson, K Gregory
Journal: British Journal of Sports Medicine (2016)

Aims To establish current physical activity (PA) behaviours in childhood cancer survivors attending a tertiary hospital “late effects” clinic. To highlight their perceived barriers to increasing physical activity levels. To identify their preferred interventions to support physical activity participation. To establish whether medical teams are providing physical activity advice as perceived by the patient. Methods Questionnaires were administered through a tertiary hospital ‘Late Effects Clinic’ for childhood cancer survivors. Questions were devised after review of previous publications relating to PA measurement and interventions.1 Results 32 responses; 17 males and 15 females between 17–45 years (median: 28 years). 56% of respondents stated becoming more physically active was a priority for them. 26% failed to meet government guidelines for PA.2 41% cited barriers to PA were ‘competing priorities’ (work, study or family/friends); 29.3% cited ‘physical barriers’ (pain, concerns about injury or medication side-effects); 19% cited ‘social barriers’ (pressure from family/friends, don't feel confident, lack of encouragement) and 10.3% cited ‘other factors’ (financial or lack of facilities/equipment). 59% stated a preference to exercise ‘on their own’ rather than through ‘group’ exercise programs which is reflected in the responses given for preferred resources to help increase PA levels; paper 33%, interactive DVD 30%, mobile phone app/online website/online website with video each 11%, podcast 4%.2 Conclusions PA is a high priority for this population and barriers broadly reflect those cited by other populations.3 Technological resources as aids to help improve PA levels need to be considered by clinicians as an important tool and should become a fundamental component of the patient pathway. Greater collaboration between SEM and other medical specialties could help identify and address the needs of specific patient groups in increasing PA levels.
Galactosylated Lipidoid Nanoparticles for Delivery of Small Interfering RNA to Inhibit Hepatitis C Viral Replication In Vivo
Authors: Hyun‐Ji Park, Eun Je Jeon, Jung Seung Lee, Sang Hyeon Hong, Ann‐Na Cho, Joan Lee, Jae‐Su Moon, Kyeong‐Eun Jung, Jong‐Won Oh, Haeshin Lee, Seung‐Woo Cho
Journal: Advanced Healthcare Materials (2016)

Small interfering RNA (siRNA) delivery can provide an effective therapy for treating viral diseases by silencing genes involved in viral replication. In this study, a liver‐targeting formulation of lipidoid nanoparticle for delivery of siRNA that targets protein kinase C‐related kinase 2 (PRK2) to inhibit hepatitis C virus (HCV) replication is reported. The most effective, minimally cytotoxic lipidoid for siRNA delivery to hepatic cells is identified from a small library of alkyl epoxide–polyamine conjugates. In vitro transfection of PRK2 siRNA (siPRK2) using this lipidoid induces significant silencing of PRK2 (≈80%), suppressing HCV replication in human hepatic cells transfected with the HCV subgenomic replicon. Systemic administration of siPRK2 using the lipidoid nanoparticles results in significant reduction of host PRK2 in the mouse liver (≈60%). This treatment significantly suppresses HCV replication in an HCV‐xenograft mouse model. siRNA delivery to the liver is further improved via galactosylation of the lipidoid. Compared with the unmodified lipidoid formulation, galactosylated lipidoids induce greater silencing of host PRK2 in mouse livers (≈80%) and more rapid suppression of HCV replication in an HCV‐xenograft mouse. This study suggests that galactosylated lipidoid nanoparticles could provide a treatment for hepatitis C by mediating delivery of anti‐viral RNA interference therapeutics to the liver.
Frequency of the JAK2V617F Mutation in Platelets from Essential Thrombocythemia (ET) Patients.
Authors: Paula G. Heller, Paola R. Lev, Juan P. Salim, Laura I. Kornblihtt, Patricia S. Vassallu, Nora P. Goette, Daniel C. Chazarreta, Ana C. Glembotsky, Rosana F. Marta, Felisa C. Molinas
Journal: Blood (2005)
Brentuximab Vedotin in Combination with Donor Lymphocyte Infusion for Patients with Hodgkin Lymphoma Relapsing after Allogeneic Stem Cell Transplantation
Authors: Panagiotis Tsirigotis, Ronit Yerushalmi, Kostantinos Gkirkas, Noga Shentov, Ivetta Danylesko, Maria Stamouli, Abraham Avigdor, Mohamad Mohty, Avichai Shimoni, Arnon Nagler
Journal: Blood (2015)
Study participants’ perceptions of the process and impact of receiving results of N9831
Authors: A. H. Partridge, A. C. Wolff, P. K. Marcom, P. A. Kaufman, C. Moore, D. Lake, G. Fleming, H. S. Rugo, D. Collyar, E. P. Winer
Journal: Journal of Clinical Oncology (2006)

518 Background: There has been growing interest in providing clinical trial participants with study results. We sought to evaluate the process of sharing results from a large cooperative group trial in an effort to guide clinicians and clinical investigators. Methods: We mailed surveys to a subset of women who participated in NCCTG 9831, Phase III Trial of Adjuvant Chemotherapy with or without Trastuzumab for Women with HER2+ Breast Cancer, after the preliminary study results were mailed to participants. Surveys were sent to all trial participants enrolled through 9 CALGB/ECOG institutions. Results: Of 228 surveys sent, 160 (70%) have been returned. Average age of respondents was 51 years (range 26–76); 84% were white; 61% were college graduates; 4% reported recurrent disease. Women reported receiving results by mail (84%), from a health care provider in person or by phone (43%), and/or from the media (47%); 2% reported that they were not informed of the results. 29% heard the results first from the media; 27% first heard by mail. 35% of women might have preferred to be offered results, with the option of not receiving them, but only 4% of women indicated that they would have declined results had they been offered first. 89% of women found the results information easy to understand; 69% correctly interpreted the results of the study; 31% either had an incorrect interpretation or were unsure of the findings. 81% of women were satisfied with how results were shared; 63% of women felt that learning results had an impact on their lives, 24% were more anxious after learning the results; 36% were less anxious. Multivariable analyses evaluating factors associated with greater satisfaction and increased anxiety will be presented. Conclusions: Sharing results is met with overwhelmingly favorable responses from patients, although a substantial proportion of patients may not initially understand the findings. Some patients desire to be offered results first, but few would decline them. The potential for increased anxiety should be considered, and psychosocial support may be required by some. A plan to share results should be routinely and prospectively included in the design of clinical trials. (Supported in part by an ASCO Career Development Award (AHP) No significant financial relationships to disclose.
Azacitidine Is Effective in Patients with Intermediate-2 / High IPSS Risk Myelodysplastic Syndrome Managed in Community Based Practice: Preliminary Data From the Spanish Azacitidine Compassionate Use Registry.
Authors: Regina Garcia, José Ramón González, Alicia Bailen, Jose F Falantes, Joaquin Sanchez, Rafael F Duarte, Juan Besalduch, Andreu Lapiedra
Journal: Blood (2009)
Retroviral Interference with Execution Pathways in Target Cells To Unravel Mechanisms of Cytotoxic T Cell-Mediated Cell Death.
Authors: J.F. de Vries, P.A. von dem Borne, M.H.M. Heemskerk, R. Willemze, J.H.F. Falkenburg, R.M.Y. Barge
Journal: Blood (2004)
High Throughput Transcriptome Sequencing of Pediatric Relapsed Acute Lymphoblastic Leukemia (ALL) Identifies Relapse Specific Mutations and Expression
Authors: Julia A. Meyer, Laura E. Hogan, Jinhua Wang, Jun J. Yang, Jay Patel, Ross L. Levine, Stephen P. Hunger, Elizabeth Raetz, Christopher Mason, William L. Carroll
Journal: Blood (2010)
Role of IL-15 in the Stimulation of Human CD8+ CMV-Reactive Human T Cells in a Hu-PBL Mouse Model Preconditioned with Self-Differentiated Human Dendritic Cells Programmed with Lentiviral Vectors
Authors: Gustavo Salguero, Borchers Sylvia, Arnold Ganser, Renata Stripecke
Journal: Blood (2011)
Phase II trial of chemoradiotherapy using weekly gemcitabine (GEM) in patients (pts) with locally advanced pancreatic cancer (PC). Final results
Authors: C. Morizane, T. Okusaka, Y. Ito, H. Ueno, M. Ikeda, Y. Takezako, M. Sumi, Y. Kagami, H. Ikeda
Journal: Journal of Clinical Oncology (2004)

4192 Background: GEM is an active agent in PC, and has known radiosensitizing properties. This study was conducted to evaluate the efficacy and toxicity of chemoradiation using weekly GEM for locally advanced PC. A previous phase I trial had determined the recommended dose of weekly GEM in a phase II chemoradiation trial to be 250 mg/m2 (Brit J Cancer 2002; 86, 1551–54). Methods: Between July 2001 and July 2002, 42 consecutive pts with histologically confirmed, unresectable locally advanced PC were enrolled in this study. GEM at a dose of 250 mg/m2 was given intravenously over 30 minutes starting 2 hours before radiotherapy weekly for 6 weeks and radiotherapy was delivered concurrently as a single course of 50.4 gray in 28 fractions. One month after completion of chemoradiation, maintenance chemotherapy with GEM at a dose of 1000 mg/m2 was administered as a 30-minute intravenous infusion weekly for 3 weeks with a 1-week rest until disease progression or unacceptable toxicity was observed. Results: Overall, grade III-IV hematological toxicities (NCI-CTC) occurred in 52% and 5% of pts, respectively. Grade III-IV non-hematological toxicities were observed in 31% and 33% of pts, respectively. There was one death attributed to duodenal bleeding and sepsis. Four pts discontinued chemoradiation because of elevated transaminase (2 pts), duodenal bleeding (1) and general fatigue (1). In 40 pts in whom tumor response was determined, 9 (21%) achieved partial response, 26 (62%) remained stable, and 5 (12%) showed progressive disease. The median survival time was 9.5 months and the 1-year survival rate was 29%. The median progression-free survival time was 5.3 months. In 35 pts with documented disease progression at the time of analysis, 34 (97%) showed distant metastasis as the cause of the initial disease progression. Conclusions: Chemoradiotherapy in this study has a moderate activity against locally advanced PC and an acceptable toxicity profile but appears to have more frequent acute toxicities compared with conventional chemoradiotherapy using 5-FU. Future investigations for treatment with more systemic effect are warranted. No significant financial relationships to disclose.
Declines in Opioid Prescribing After a Private Insurer Policy Change — Massachusetts, 2011–2015
Authors: Macarena C. García, Anton B. Dodek, Tom Kowalski, John Fallon, Scott H. Lee, Michael F. Iademarco, John Auerbach, Michele K. Bohm
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

Overdose deaths involving opioid pain medications are epidemic in the United States, in part because of high opioid prescribing rates and associated abuse of these drugs (1). In 2014, nearly 2 million U.S. residents either abused or were dependent on prescription opioids (2). In Massachusetts, unintentional opioid-related overdose deaths, including deaths involving heroin, increased 45% from 2012 to 2013.* In 2014, the rate of these deaths reached 20.0 per 100,000, nearly 2.5 times higher than the U.S. rate overall (3,4). On July 1, 2012, Blue Cross Blue Shield of Massachusetts (BCBSMA), the largest insurer in the state with approximately 2.8 million members,† implemented a comprehensive opioid utilization program after learning that many of its members were receiving new prescriptions with a >30-day supply of opioids. The 2016 CDC Guideline for Prescribing Opioids for Chronic Pain recommends avoiding opioids as a first-line therapy for chronic pain and limiting quantities when initiating opioids for acute pain (5). CDC analyzed BCBSMA prescription claims data for the period 2011-2015 to assess the effect of the new utilization program on opioid prescribing rates. During the first 3 years after policy implementation, the average monthly prescribing rate for opioids decreased almost 15%, from 34 per 1,000 members to 29. The percentage of BCBSMA members per month with current opioid prescriptions also declined. The temporal association between implementation of the program and statistically significant declines in both prescribing rates and proportion of members using opioids suggests that the BCBSMA initiative played a role in reducing the use of prescription opioids among its members. Public and private insurers in the United States could benefit from developing their own best practices for prescription opioid utilization that ensure accessible pain care, while reducing the risk for dependence and abuse associated with these drugs.
DR3 signaling modulates the function of Foxp3+ regulatory T cells and the severity of acute graft-versus-host disease
Authors: Hidekazu Nishikii, Byung-Su Kim, Yasuhisa Yokoyama, Yan Chen, Jeanette Baker, Antonio Pierini, Maite Alvarez, Melissa Mavers, Kristina Maas-Bauer, Yuqiong Pan, Shigeru Chiba, Robert S. Negrin
Journal: Blood (2016)
The prognostic impact of percentage of involved axillary lymph nodes for breast cancer patients treated with radiotherapy
Authors: A. Haydaroglu, Y. Bolukbasi, S. Demirci, M. Esassolak, Z. Ozsaran, B. Aydin, A. Aras
Journal: Journal of Clinical Oncology (2008)

582 Background: The number of positive nodes is an important tool used in the staging of breast cancer. However, this number depends on the number of the lymph nodes dissected. Therefore there is a rising interest of evaluation of the percentage of involved nodes. This study focuses on the prognostic significance of the percentage of involved nodes [p(N+): (the ratio of # of pathologically involved axillary lymph nodes to the # of axillary lymph nodes dissected) x100] among breast cancer patients treated with postmastectomy radiotherapy (PMRT). Methods: A retrospective review of 1,494 breast cancer patients treated with PMRT during 1982–2002 was undertaken of which 1,161 patients were found to have positive nodes. Evaluation of the percent positive nodes has previously been shown to be more reliable in patients with more than 10 nodes dissected; therefore we restricted our analyses in such cohort of 950 patients. These patients were categorized based on percent positive nodes into three groups:, p(N+)<= 20% (n=319), between 21–50% (n=335), and more than 50% (n=296). Results: Among the 950 patients analyzed, 5-year disease-free survival (DFS) and overall survival (OS) were 59.4% and 81.4%, respectively. DFS and OS rates for p(N+)50 were 69.4% vs 62.6% vs 44.8% (p=0.007); 88.3% vs 86.3% vs 68.5% (p<0.001), respectively. Additionally, skin invasion, T stage, N stage, stage, lymphovascular invasion, number of involved nodes (1–3 vs 4–9 vs 10+) were significantly associated with both DFS and OS. In a multivariate analysis using Cox regression model, lymphovascular invasion (p=0.02) and p(N+) (p=0.007) were found to be significantly associated with DFS. Lymphovascular invasion (p=0.01), histologic grade (p=0.01), and p(N+) (p=0.01) were all significantly associated with OS. Conclusions: Based on our results, we believe that the p(N+) appears to be an important prognostic factor. This factor may be especially important in the context of the decision to use PMRT in 1–3 (+) LN group of the patients, which is still controversial. No significant financial relationships to disclose.
Long Term Follow-up of Allogeneic Transplantation Using BEAM Chemotherapy for Patients with Hodgkin's Lymphoma Who Relapse After Autologous Transplantation: Importance of Minimal Residual Disease At Transplant.
Authors: Urszula A Sobol, Tulio E. Rodriguez, Scott E. Smith, Aileen Go, Ross Vimr, Mala Parthasarathy, Rong Guo, Patrick Stiff
Journal: Blood (2012)
Absolute Lymphocyte Count Recovery during Standard Chemotherapy Predicts Superior Survival and Is Independent of the Hasenclever Index for Hodgkin’s Disease.
Authors: Mustaqeem Siddiqui, Luis F. Porata, Kay Ristow, Thomas M. Habermann, Joseph P. Colgan, William L. White, Thomas E. Witzig, David J. Inwards, Stephen M. Ansell, Ivana N. Micallef, Patrick B. Johnston, William G. Martin, James A. Martenson, Scott L. Stafford, Svetomir N. Markovic
Journal: Blood (2005)
Economic Burden and Cost Determinants of Deep Venous Thrombosis During the Two Years Following Diagnosis: a Prospective Evaluation
Authors: Raphael Guanella, Thierry Ducruet, Mira Johri, Marie Jose Miron, Andre Roussin, Sylvie Desmarais, France Joyal, Jeannine Kassis, Susan Solymoss, Louis Desjardins, Jeffrey S. Ginsberg, Donna L. Lamping, Ian Shrier, Susan R. Kahn
Journal: Blood (2010)